Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 13/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | USP8 | P40818 | 1/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315714 | 0.94 | HPGDS (0.40) | FGFR3HPGDSFGFR4 | |
| SCHEMBL1126250 | 0.90 | FGFR3 (0.37) | FGFR3HPGDSSCN5ASCN9AFGFR4 | |
| SCHEMBL14212772 | 0.88 | HPGDS (0.38) | FGFR3HPGDSFGFR4 | |
| SCHEMBL1126188 | 0.84 | FGFR3 (0.38) | FGFR3HPGDSFGFR4 | |
| SCHEMBL1126172 | 0.82 | FGFR3 (0.38) | FGFR3HPGDSFGFR4 | |
| SCHEMBL13626907 | 0.80 | FGFR3 (0.40) | FGFR3HPGDSFGFR4 | |
| SCHEMBL1126531 | 0.80 | FGFR3 (0.40) | FGFR3HPGDSFGFR4 | |
| SCHEMBL14212758 | 0.79 | CRHR1 (0.36) | FGFR3HPGDSFGFR4 | |
| SCHEMBL13626908 | 0.78 | FGFR3 (0.40) | FGFR3HPGDSFGFR4 | |
| SCHEMBL1126110 | 0.78 | FGFR3 (0.40) | FGFR3HPGDSFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282995-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |